Search Results - "Pharmacoepidemiology and drug safety"

Refine Results
  1. 1

    The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology by Bezin, Julien, Duong, Mai, Lassalle, Régis, Droz, Cécile, Pariente, Antoine, Blin, Patrick, Moore, Nicholas

    Published in Pharmacoepidemiology and drug safety (01-08-2017)
    “…The French health care system is based on universal coverage by one of several health care insurance plans. The SNIIRAM database merges anonymous information…”
    Get full text
    Journal Article
  2. 2

    The Chang Gung Research Database—A multi‐institutional electronic medical records database for real‐world epidemiological studies in Taiwan by Shao, Shih‐Chieh, Chan, Yuk‐Ying, Kao Yang, Yea‐Huei, Lin, Swu‐Jane, Hung, Ming‐Jui, Chien, Rong‐Nan, Lai, Chi‐Chun, Lai, Edward Chia‐Cheng

    Published in Pharmacoepidemiology and drug safety (01-05-2019)
    “…Purpose The Chang Gung Research Database (CGRD), the largest multi‐institutional electronic medical records (EMR) collection in Taiwan, provides good access…”
    Get full text
    Journal Article
  3. 3

    Trial designs using real‐world data: The changing landscape of the regulatory approval process by Baumfeld Andre, Elodie, Reynolds, Robert, Caubel, Patrick, Azoulay, Laurent, Dreyer, Nancy A.

    Published in Pharmacoepidemiology and drug safety (01-10-2020)
    “…Purpose There is a need to develop hybrid trial methodology combining the best parts of traditional randomized controlled trials (RCTs) and observational study…”
    Get full text
    Journal Article
  4. 4

    A synthesis of oral morphine equivalents (OME) for opioid utilisation studies by Nielsen, Suzanne, Degenhardt, Louisa, Hoban, Bianca, Gisev, Natasa

    Published in Pharmacoepidemiology and drug safety (01-06-2016)
    “…Purpose Oral Morphine Equivalent (OME) doses are increasingly being used as a metric to represent opioid use. Driven by a growing need from…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions by Wu, Jasmanda, Wang, Cunlin, Toh, Sengwee, Pisa, Federica Edith, Bauer, Larry

    Published in Pharmacoepidemiology and drug safety (01-10-2020)
    “…Following the release of the framework for the Real‐World Evidence (RWE) Program, the US Food and Drug Administration (FDA) is actively evaluating and…”
    Get full text
    Journal Article
  7. 7

    Validation of the national health insurance research database with ischemic stroke cases in Taiwan by Cheng, Ching-Lan, Kao, Yea-Huei Yang, Lin, Swu-Jane, Lee, Cheng-Han, Lai, Ming Liang

    Published in Pharmacoepidemiology and drug safety (01-03-2011)
    “…Objective The National Health Insurance Research Database (NHIRD) is commonly used for pharmacoepidemiological research in Taiwan. This study evaluated the…”
    Get full text
    Journal Article
  8. 8

    Prevalent new‐user cohort designs for comparative drug effect studies by time‐conditional propensity scores by Suissa, Samy, Moodie, Erica E. M., Dell'Aniello, Sophie

    Published in Pharmacoepidemiology and drug safety (01-04-2017)
    “…Purpose Studies of the real‐world comparative effectiveness of drugs conducted using computerized healthcare databases typically involve an incident new‐user…”
    Get full text
    Journal Article
  9. 9

    Time‐related biases in pharmacoepidemiology by Suissa, Samy, Dell'Aniello, Sophie

    Published in Pharmacoepidemiology and drug safety (01-09-2020)
    “…Purpose Observational studies using computerized healthcare databases have become popular to investigate the potential effectiveness of old drugs for new…”
    Get full text
    Journal Article
  10. 10

    Real‐world evidence to support regulatory decision‐making for medicines: Considerations for external control arms by Burcu, Mehmet, Dreyer, Nancy A., Franklin, Jessica M., Blum, Michael D., Critchlow, Cathy W., Perfetto, Eleanor M., Zhou, Wei

    Published in Pharmacoepidemiology and drug safety (01-10-2020)
    “…Randomized clinical trials (RCTs) are the gold standard in producing clinical evidence of efficacy and safety of medical interventions. More recently, a new…”
    Get full text
    Journal Article
  11. 11

    Accuracy of Japanese claims data in identifying diabetes‐related complications by Fujihara, Kazuya, Yamada‐Harada, Mayuko, Matsubayashi, Yasuhiro, Kitazawa, Masaru, Yamamoto, Masahiko, Yaguchi, Yuta, Seida, Hiroyasu, Kodama, Satoru, Akazawa, Kohei, Sone, Hirohito

    Published in Pharmacoepidemiology and drug safety (01-05-2021)
    “…Purpose To evaluate the accuracy of various claims‐based definitions of diabetes‐related complications (coronary artery disease [CAD], heart failure,…”
    Get full text
    Journal Article
  12. 12

    Use of real‐world evidence from healthcare utilization data to evaluate drug safety during pregnancy by Huybrechts, Krista F., Bateman, Brian T., Hernández‐Díaz, Sonia

    Published in Pharmacoepidemiology and drug safety (01-07-2019)
    “…Purpose Because preapproval clinical trials typically exclude pregnant women, the evidence on drug safety during pregnancy required to inform drug labeling…”
    Get full text
    Journal Article
  13. 13

    Long‐term opioid therapy definitions and predictors: A systematic review by Karmali, Ruchir N., Bush, Christopher, Raman, Sudha R., Campbell, Cynthia I., Skinner, Asheley C., Roberts, Andrew W.

    Published in Pharmacoepidemiology and drug safety (01-03-2020)
    “…Purpose This review sought to (a) describe definitions of long‐term opioid therapy (LTOT) outcome measures, and (b) identify the predictors associated with the…”
    Get full text
    Journal Article
  14. 14
  15. 15

    One-to-many propensity score matching in cohort studies by Rassen, Jeremy A., Shelat, Abhi A., Myers, Jessica, Glynn, Robert J., Rothman, Kenneth J., Schneeweiss, Sebastian

    Published in Pharmacoepidemiology and drug safety (01-05-2012)
    “…ABSTRACT Background Among the large number of cohort studies that employ propensity score matching, most match patients 1:1. Increasing the matching ratio is…”
    Get full text
    Journal Article
  16. 16

    Characteristics and external validity of the German Health Risk Institute (HRI) Database by Andersohn, Frank, Walker, Jochen

    Published in Pharmacoepidemiology and drug safety (01-01-2016)
    “…Purpose The aim of this study was to describe characteristics and external validity of the German Health Risk Institute (HRI) Database. Methods The HRI…”
    Get full text
    Journal Article
  17. 17

    Methods for time‐varying exposure related problems in pharmacoepidemiology: An overview by Pazzagli, Laura, Linder, Marie, Zhang, Mingliang, Vago, Emese, Stang, Paul, Myers, David, Andersen, Morten, Bahmanyar, Shahram

    Published in Pharmacoepidemiology and drug safety (01-02-2018)
    “…Purpose Lack of control for time‐varying exposures can lead to substantial bias in estimates of treatment effects. The aim of this study is to provide an…”
    Get full text
    Journal Article
  18. 18

    Validity of cancer diagnosis in the National Health Insurance database compared with the linked National Cancer Registry in Taiwan by Kao, Wei‐Heng, Hong, Ji‐Hong, See, Lai‐Chu, Yu, Huang‐Ping, Hsu, Jun‐Te, Chou, I‐Jun, Chou, Wen‐Chi, Chiou, Meng‐Jiun, Wang, Chun‐Chieh, Kuo, Chang‐Fu

    Published in Pharmacoepidemiology and drug safety (01-10-2018)
    “…Purpose We aimed to evaluate the validity of cancer diagnosis in the National Health Insurance (NHI) database, which has routinely collected the health…”
    Get full text
    Journal Article
  19. 19

    Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparators by Sendor, Rachel, Stürmer, Til

    Published in Pharmacoepidemiology and drug safety (01-03-2022)
    “…Confounding by indication poses a significant threat to the validity of nonexperimental studies assessing effectiveness and safety of medical interventions…”
    Get full text
    Journal Article
  20. 20